Clinical Trial: Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07868926) titled 'Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose' on Oct. 05.

Brief Summary: The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.

Study Start Date: Oct. 19

Study Type: INTERVENTIONAL

Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Intervention: DRUG: 14C-VX-407

Solution for Oral Administration.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Vertex Pharmaceuticals Incorporated

Disclaimer: Curated by HT Syndication....